Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 in Advanced Solid Tumors
NCT02277717Phase 1Completed
- Sponsor
- Byondis
- Start
- Oct 2014
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab duocarmazine in solid tumor, breast cancer, gastric cancer (GC) and 2 more, sponsored by Byondis. Primary endpoint: Incidence of dose-limiting toxicities at 21 days. Started Oct 2014; status: completed.
02
Drugs
trastuzumab duocarmazine
03
Conditions
solid tumorbreast cancergastric cancer (GC)urothelial carcinoma (UC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02277717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277717.